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Photosensitivity from Nalidixic Acid [Abridged] by C A Ramsay MB MRCP (Department ofPhotobiology, Institute of Dermatology, Homerton Grove, London E9 6BX) Seven patients with photosensitivity from nalidixic acid seen since 1968 were reported. All were females and all showed blisters on the dorsa of the feet; the lower legs and the dorsa of the hands were also frequently affected. The eruption frequently started when the patient was on holiday and a high level of ambient sunlight seemed to be more important than the length of time that the drug had been taken. Blisters often continued to appear for several months after the drug had been stopped and fragility of the skin was seen in 4 patients. Porphyrin excretion was normal in all patients. Photopatch tests were performed in 3 patients and were negative.
Skin tests with narrow waveband artificial ultraviolet were carried out in all patients and reactions to longwave u.v. were detected in 3 of them. Two volunteers took the drug in a dose of 4 g daily for one week and at the end of this time immediate erythematous reactions to longwave u.v. were present in both volunteers, the significance of which is uncertain. Definite abnormal delayed erythematous reactions to a broad spectrum long u.v. source was detected in both volunteers after the drug had been taken. Further investigations with this source in another volunteer are being undertaken.
Although the mechanism underlying the photosensitivity from nalidixic acid is unknown, the eruption usually presents a very characteristic clinical picture. Our experience suggests that patients may continue to take the drug providing that they avoid direct sunlight on the skin. It would probably be wise to give similar advice to all patients taking the drug. Psoriasis is characterized by proliferation of epidermal cells with greatly increased rate of cell turnover. The most successful treatments of psoriasis reduce the epidermal turnover time by chemical or physical means. Cell poisons such as mercury, arsenic, phenolic compounds, methotrexate, azathioprine and corticosteroids all help in the therapy of psoriasis.
Some cytotoxic compounds such as corticosteroids and azathioprine have an immunosuppressive action as well as interfering with nuclear protein synthesis, and it may be impossible to distinguish which of these two actions is responsible for a therapeutic response.
The use of cytotoxic drugs, of the type developed for cancer therapy, was a major advance in the management of severe psoriasis, and methotrexate especially appeared to be an effective drug with high patient tolerance and low incidence of complications. From 1951 when Gubner et al. described its use in psoriasis, dermatologists gradually became more familiar with the efficient use of the drug, but in 1964 O'Rourke & Eckert reported serious hepatic changes in a psoriatic patient who received methotrexate. This confirmed a similar finding in leukvmic children treated with the same drug (Colsky et al. 1955) . Since this initial report, the hepatotoxic action of methotrexate has been reported increasingly often when this form of toxicity is specifically sought (Dahl et al. 1971 (Dahl et al. , 1972 .
The value of other cytotoxic drugs in relationship to their toxic actions has therefore been studied in psoriasis, and the present project was undertaken to evaluate azathioprine in the management of severe psoriasis, taking particular note of evidence suggesting liver damage caused by the drug.
Azathioprine is an imidazolyl derivative of mercaptopurine and in vivo 90 % is converted into 6-mercaptopurine and 10% excreted unchanged in the urine. About half of the mercaptopurine is excreted within twenty-four hours but the therapeutic action continues long after the drug has been cleared from the blood. Mercaptopurine is an analogue of hypoxanthine and a competitive inhibitor. The ribonucleotide of hypoxanthine is the first biosynthetic purine and the core of all purine metabolism. By interference with this ,metabolism DNA and RNA synthesis is inhibited.
Toxic actions of the drug include bone marrow hypoplasia, hepatotoxicity, gastrointestinal upsets, reduced resistance to infection, malignant tumours and teratogenicity. The usual dose given orally is 1-5 mg/kg per day. Patients and treatment: Twenty-nine patients with an average age of 51 years (range 23-79 years) were studied. Sixteen men and 13 women formed the group, of whom 6 were under 40 years. Women of childbearing age were advised to remain on a contraceptive pill throughout the period ofmedication.
All patients had severe psoriasis which had failed to respond to simpler treatment or to methotrexate. Cases who were taking systemic
